



# Evaluation of the Performance of Ortho *T. cruzi* ELISA Test System for the Detection of Antibodies to *Trypanosoma cruzi*

Hilda N. Rivera,<sup>a</sup> Isabel McAuliffe,<sup>a</sup> TaLesia Aderohunmu,<sup>a,b</sup> Ryan E. Wiegand,<sup>c</sup> Susan P. Montgomery,<sup>a</sup> Richard S. Bradbury,<sup>d</sup> Sukwan Handali<sup>a</sup>

<sup>a</sup>Parasitic Diseases Branch, Division of Parasitic Diseases & Malaria, Center for Global Health, Centers for Disease Control & Prevention, Atlanta, Georgia, USA

<sup>b</sup>IHRC, Atlanta, Georgia, USA

<sup>c</sup>Office of the Director, Division of Parasitic Diseases & Malaria, Center for Global Health, Centers for Disease Control & Prevention, Atlanta, Georgia, USA

<sup>d</sup>School of Science, Psychology and Sport, Federation University Australia, Berwick, Australia

**ABSTRACT** The serologic diagnosis of chronic Chagas disease, caused by infection with the parasite *Trypanosoma cruzi*, is challenging and lacks a gold-standard assay. To overcome the problem, CDC uses an algorithm that uses two tests on different platforms and applies a third test as a tiebreaker. The Ortho *T. cruzi* ELISA Test System from Ortho Diagnostics was cleared by FDA for clinical diagnosis usage. We evaluated this test against the CDC algorithm for chronic Chagas disease. We tested several sets of serum specimens: 104 specimens tested positive for *T. cruzi* specific antibody and 283 (including 30 specimens positive for antibody to *Leishmania* spp.) tested negative based on the current CDC chronic *T. cruzi* infection diagnostic testing algorithm. Concordance of the Ortho *T. cruzi* ELISA Test System with the CDC algorithm result was 90% (95% CI 87 to 93%) overall and 92% (95% CI 89 to 95%) when excluding *Leishmania* spp. antibody positive specimens. The cross-reactivity of the Ortho *T. cruzi* ELISA Test System was 37% to *Leishmania* spp. serologically positive specimens, 1% to specimens from patients diagnosed with other parasitic infections, and 0% against specimens from a US noninfected population. In conclusion, the Ortho *T. cruzi* ELISA Test System compares well against the CDC diagnostic algorithm for chronic Chagas disease. The availability of this FDA-cleared assay will improve the chronic Chagas disease diagnosis.

**KEYWORDS** ELISA, *Trypanosoma cruzi*, antibodies detection, assay performance

Chagas disease is a parasitic infection caused by the protozoan parasite *Trypanosoma cruzi* transmitted to animals and people by triatomine vectors. Transmission mainly occurs in rural areas of Mexico, Central America, and South America. Based on Pew Research Center estimates of undocumented Latin American immigrants in the United States and WHO country Chagas disease prevalence, the total number of persons with Chagas disease living in the United States is between 326,000 and 347,000 (1). The vast majority of these infections are acquired in Latin America (1–4). There have also been at least 76 cases of autochthonous transmission in the United States (5).

The selection of tests for laboratory diagnosis depends on the stage of the disease. Acute infection, typically the first 4 to 8 weeks (6), is best diagnosed using direct parasitological techniques and/or polymerase chain reaction (PCR) of blood. During the chronic phase of infection, which can last for decades, parasites reside primarily in tissue and are rarely seen in the blood, so diagnosis during this phase relies on detecting circulating *T. cruzi*-specific IgG antibodies (7, 8). Because no single test has optimal sensitivity and specificity, WHO recommends that diagnosis of chronic infection be based on the concordant results of two different serologic tests, preferably using different formats (9).

In the United States, the current FDA-approved tests for blood donor screening are the Ortho *T. cruzi* ELISA Test System, Abbott Alinity s Chagas, Abbott PRISM Chagas,

**Editor** Bobbi S. Pritt, Mayo Clinic

This is a work of the U.S. Government and is not subject to copyright protection in the United States. Foreign copyrights may apply.

Address correspondence to Sukwan Handali, ahi0@cdc.gov.

The authors declare no conflict of interest.

**Received** 25 January 2022

**Returned for modification** 8 February 2022

**Accepted** 14 June 2022

**Published** 12 July 2022

and Abbott ESA Chagas. The Ortho *T. cruzi* ELISA Test System uses whole parasite lysate antigens of *T. cruzi* Tulaheun strain (10, 11), while both Abbott tests use the same four recombinant antigens but different assay formats (12). For clinical diagnostic testing, FDA-cleared tests to detect *Trypanosoma cruzi* specific IgG include Hemagen Chagas kit (Hemagen Diagnostics, Inc, Columbia MD) and InBios Chagas Detect Plus Rapid Test (InBios International Inc., Seattle, WA), and to detect total immunoglobulins, Wiener Chagatest ELISA recombinante v.3.0 (Wiener Laboratorios SAIC, Argentina). The Hemagen Chagas kit is an ELISA using an epimastigote lysate antigen preparation, and the Wiener Chagatest ELISA recombinante v.3.0 uses six purified recombinant antigens targets. The InBios Chagas Detect is an immunochromatographic strip assay that uses a recombinant multiepitope fusion antigen to detect antibodies (13). In May 2009, the Ortho *T. cruzi* ELISA Test System was cleared by the FDA for use as a diagnostic test, but the company has elected not to market the kit for *in vitro* diagnostic use.

The CDC Parasitic Diseases Reference Diagnostic Laboratory acts as a national reference laboratory. For Chagas disease serology, the CDC receives specimens that test positive on a single assay at a commercial laboratory for confirmatory testing and performs Chagas disease serology using two tests, Wiener the Chagatest ELISA recombinante v.3.0 and a laboratory-developed test, *T. cruzi* excretory-secretory antigens (TESA) immunoblot. When results from these two tests are concordant, the final report reflects that concordant result. When the results are discordant, another laboratory-developed test, an immunofluorescence assay [IFA] using whole trypomastigote lysate antigens, is used as a tiebreaker. According to the manufacturer, the Wiener Chagatest ELISA recombinante v.3.0 has 99% sensitivity and 96% specificity. The TESA immunoblot has 97% sensitivity and specificity, while IFA has 94% sensitivity and 95% specificity (14). Wiener Chagatest ELISA recombinante v.3.0 and TESA immunoblot results show good agreement with 96% concordance on testing specimens sent to the CDC from 2012 to 2017 (unpublished data).

We sought to evaluate the Ortho *T. cruzi* ELISA Test System as a diagnostic test for chronic Chagas disease. The Ortho *T. cruzi* ELISA Test System kit insert states test characteristics are 100% sensitivity (based on testing 106 positive specimens from subjects from Bolivia, Chile, Colombia, and Nicaragua) and 99.9% specificity with 0.007% non-specific binding among 40,662 volunteer blood donors. In addition, the manufacturer reported 79% cross-reactivity for antibodies to *Leishmania* spp. (using sera collected in India, where Chagas disease is not endemic).

The primary objective was to determine the concordance of the Ortho *T. cruzi* ELISA Test System with the CDC Chagas disease serology algorithm. A secondary objective was to determine how the Ortho *T. cruzi* ELISA Test System compared to CDC testing in detecting *T. cruzi* specific antibodies in patients from various geographic regions, including North America.

## MATERIALS AND METHODS

**Ethics statement.** All specimens used in this study were de-identified residual patient specimens submitted to the CDC Parasitic Diseases Reference Diagnostic Laboratory for diagnostic testing. The use of de-identified specimens for assay evaluation in this study was permissible under CDC Study Protocol number 6756.

**Serum specimens.** Three sets of convenience specimens were used for the evaluation of the Ortho *T. cruzi* ELISA Test System. First, a set of 104 defined positive sera based on CDC Chagas disease serology results. This set consisted of two groups: the first group included specimens that tested positive on both Wiener Chagatest ELISA recombinante v.3.0 and TESA immunoblot (N = 87), and the second group included specimens with initial discordant results on the two tests but positive results on the IFA tiebreaker test (N = 17). The specimens were deliberately selected based on the patient's reported travel history to indicate where the infection was likely acquired (US, Mexico, and Central America exposure). The second set consisted of 253 specimens defined as negative sera. Of these, 223 sera had negative results on both assays at CDC, and 30 had discordant results and tested negative by the IFA tiebreaker (13 sera positive by Wiener Chagatest ELISA recombinante v.3.0 but negative by TESA immunoblot and 17 sera negative by Wiener Chagatest ELISA recombinante v.3.0 but positive by TESA immunoblot). Specimen classified as Chagas negative sera potentially had positive results either by Hemagen or Wiener Chagatest ELISA recombinante v.3.0 prior to CDC submission.

The third set consisted of 30 specimens from patients diagnosed with *Leishmania* spp. infection based on the CDC IFA assay and negative for chronic Chagas disease based on the CDC Chagas disease serology algorithm. The infecting *Leishmania* spp. were *L. braziliensis*, *L. tropica major*, *L. m. mexicana*,

**TABLE 1** Concordance of Ortho *T. cruzi* ELISA<sup>a</sup> Test System results with the CDC test results

Specimen source	CDC Chagas disease test results			Final CDC result	Total N	Ortho positive N (%)	Ortho negative N (%)
	Wiener	TESA <sup>b</sup>	IFA <sup>c</sup>				
Submitted for <i>T. cruzi</i> confirmatory testing	Positive	Positive	ND <sup>d</sup>	Positive	87	<b>85 (97.7)<sup>e</sup></b>	2 (2.3)
	Positive	Negative	Positive	Positive	10	<b>6 (60.0)</b>	4 (40.0)
	Negative	Positive	Positive	Positive	7	<b>6 (85.7)</b>	1 (14.3)
	Positive	Negative	Negative	Negative	13	4 (30.8)	<b>9 (69.2)</b>
	Negative	Positive	Negative	Negative	17	12 (70.6)	<b>5 (29.4)</b>
	Negative	Negative	ND	Negative	223	4 (1.8)	<b>219 (98.2)</b>
Leishmaniasis seropositive	Negative	Negative	ND	Negative	30	11 (36.7)	<b>19 (63.3)</b>

<sup>a</sup>ELISA, enzyme-linked immunosorbent assay.

<sup>b</sup>TESA, *T. cruzi* excretory-secretory antigens.

<sup>c</sup>IFA, immunofluorescence assay.

<sup>d</sup>ND, not done.

<sup>e</sup>Bolded figures indicate concordance.

and *L. panamensis*. The geographic regions where patients acquired *Leishmania* spp. infection were unknown. The detailed categories of all sera used are in Table 1.

**Testing procedure.** Testing was performed according to the manufacturer's instructions. Briefly, all reagents were brought to room temperature before the experiment. First, 200  $\mu$ L/well of specimen diluent was added to the 96-well plate. Then, 20  $\mu$ L of the specimen (negative controls and positive calibrators included in the kit, and sera to be tested) was added to the well, and the optical density (OD) of the well (OD<sub>610 nm</sub>) was measured without blanking as the first quality control (QC) check (serum omission monitoring = SOM). Next, the plate was covered with a plate sealer and then incubated for 60 min at 37°C. After washing five times with 700  $\mu$ L/well wash buffer using an automatic plate washer, 200  $\mu$ L/well of mouse anti-human IgG labeled with horseradish peroxidase conjugate was added to all wells except the blank well. The second QC check (conjugate omission monitoring = COM) measured the OD<sub>490 nm</sub> without blanking. Next, the plate was incubated for 30 min at 37°C, washed as in the previous step, and then 200  $\mu$ L/well of substrate solution (o-phenylenediamine tablets added to citrate-phosphate buffer containing 0.02% hydrogen peroxide) were added into all wells. After incubating the plate for 30 min in the dark at room temperature, the reaction was stopped by adding 50  $\mu$ L/well of 4N H<sub>2</sub>SO<sub>4</sub> into all wells. The result was read at OD<sub>490 nm</sub> with blanking and with a reference wavelength at 620 nm.

**Data analysis.** The cutoff point for differentiating between negative and positive results was determined by multiplying the average OD<sub>490/620</sub> of positive calibrators by 0.425 (the cutoff constant) as per the manufacturer's instructions. Specimens with OD  $\geq$  the cutoff point were called reactive (positive), and specimens with OD < the cutoff point were called nonreactive (negative).

Analyses reported the frequency and percentage of positive sera for each test, Wiener Chagatest ELISA recombinante v.3.0, TESA immunoblot, and Ortho *T. cruzi* ELISA Test System. Comparisons between tests used concordance, the proportion of patients with the same result. Thus, the numerator was the number of tests where a patient was positive or negative on both tests, and the total number of tests was the denominator. Confidence intervals were calculated using Wilson's method with Yates' continuity correction (15, 16). Analyses were reported for all tests together and then broken out by location based on travel history (when known). The agreement between the Ortho *T. cruzi* ELISA Test System and the final CDC reported Chagas disease serology algorithm result with all available specimens and without *Leishmania* spp. positive specimens are reported. The second set of analyses compared Ortho *T. cruzi* ELISA Test System to the final CDC reported algorithm result, again on the subset of patients with Wiener Chagatest ELISA recombinante v.3.0 and TESA results from immunoblot were concordant. Finally, the third analysis compared the Ortho *T. cruzi* ELISA Test System to the final CDC reported algorithm result on the subset of patients where Wiener Chagatest ELISA recombinante v.3.0 and TESA immunoblot disagree. All analyses were done in R version 4.1.0, and all confidence intervals are two-sided and use the 5% level of significance (17). Comparisons between regions were made with Fisher's Exact test, except when comparing the discordance between Ortho *T. cruzi* ELISA Test System and the final CDC reported algorithm when McNemar's test was used.

## RESULTS

The agreement between the CDC final algorithm and the Ortho *T. cruzi* ELISA Test System results and the specimen origins can be found in Table 1 and 2. Overall concordance was 90% (95% confidence interval [CI] = 87 to 93%). When the analyses did not include *Leishmania* spp. positive sera, the overall concordance was 92% (CI: 89 to 95%). Cross-reactivity of *Leishmania* spp. positive sera to Ortho *T. cruzi* ELISA Test System was 11/30 (37%) while all those sera were negative by the CDC algorithm. Considering the specimens with concordant results on Wiener Chagatest ELISA recombinante v.3.0 and TESA immunoblot ( $n = 340$ ), the concordance between the CDC final algorithm diagnosis and diagnosis the Ortho *T. cruzi* ELISA Test System was 95% (CI: 92 to 97%).

**TABLE 2** The performance of Ortho *T. cruzi* ELISA<sup>a</sup> test system against the CDC test results

Test	Ortho result and test performance	CDC tests results	
		Positive	Negative
Ortho	Positive	97	20
	Negative	7	233
	Sensitivity (Positive Percent Agreement)	93.3%	95% CI <sup>b</sup> = 86.6%–97.3%
	Specificity (Negative Percent Agreement)	92.1%	95% CI = 88.1%–95.1%

<sup>a</sup>ELISA, enzyme-linked immunosorbent assay.

<sup>b</sup>CI, confidence interval.

Concordance of the CDC final result with the Ortho *T. cruzi* ELISA Test System result was similar when broken out by different regions of reported travel history (Table 3). Furthermore, considering only the specimens (218/340) with information on the exposure region, 35 tested positive using the CDC algorithm and Ortho, giving a 99 to 100% agreement. However, the agreement is lower at 88% for subgroups with unknown or mixed travel histories (Table 3).

## DISCUSSION

In our evaluation, Ortho *T. cruzi* ELISA Test System results were comparable to CDC diagnostic algorithm results for diagnosing chronic Chagas when CDC test results were concordant. Variation in the sensitivity of specific serological assays for detecting *T. cruzi* antibodies has been observed in several studies, especially when testing specimens collected from patients in Mexico and Central America (18–23). Our data showed that the Ortho *T. cruzi* ELISA Test System performed similar to the CDC algorithm to detect *T. cruzi* antibody in specimens from individuals with reported travel history in North and Central America regions compared to South America (Tables 3). However, this observation is based on a small sample size and many unknown travel/country of origin in the set of samples used for the study.

There are several potential biases of this study. First, the selection of specimens that favors Hemagen or Wiener Chagatest ELISA recombinant v.3.0 in prior screening could affect the result of the comparison. Second, the specimens have more information of unknown country origins and travel history. This lack of information could also add to the bias in the analysis of the results.

In conclusion, the Ortho *T. cruzi* ELISA Test System was comparable to the Chagas disease serology assay algorithm currently used to detect antibodies to *T. cruzi* at the CDC. In addition, the assay was comparable to the CDC Chagas disease serology algo-

**TABLE 3** Concordance of Ortho *T. cruzi* ELISA<sup>a</sup> test system results with the final CDC results according to region of origin

Region and results by the CDC tests	Total N	Ortho positive N (%)	Ortho negative N (%)
Among CDC-positive specimens			
Central America	23	<b>21 (91.3)<sup>b</sup></b>	2 (8.7)
North America	16	<b>15 (93.8)</b>	1 (6.2)
South America	6	<b>5 (83.3)</b>	1 (16.7)
Unknown/Mixed travel	59	<b>56 (94.9)</b>	3 (5.1)
Overall	104	<b>97 (93.3)</b>	7 (6.7)
Among CDC-negative specimens			
Central America	11	3 (27.3)	<b>8 (72.7)</b>
North America	184	5 (2.7)	<b>179 (97.3)</b>
South America	7	1 (14.3)	<b>6 (85.7)</b>
Unknown/Mixed travel	51	11 (21.6)	<b>40 (78.4)</b>
Overall	253 <sup>c</sup>	20 (7.9)	<b>233 (92.1)</b>

<sup>a</sup>ELISA, enzyme-linked immunosorbent assay.

<sup>b</sup>Bolded figures indicate concordance.

<sup>c</sup>Not including leishmaniasis seropositive specimens.

rithm in detecting antibodies from subjects infected in different regions of America. Because of the potential for false positives in individuals with *Leishmania* spp. infection, a test algorithm that includes a test that does not cross-react with exposure to *Leishmania* spp. (such as TESA immunoblot) will produce an excellent antibody detection for subjects with chronic Chagas infection. Additional studies comparing the Ortho *T. cruzi* ELISA Test System test to those based on non-South American strains will help in fully understanding the usefulness of the new test system.

## ACKNOWLEDGMENTS

We are grateful for the donation of the Ortho *T. cruzi* ELISA Test System from Paul Constable (Ortho Diagnostic).

Use of trade names is for identification only and does not imply endorsement by the Public Health Service or the US Department of Health and Human Services. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

## REFERENCES

- Manne-Goehler J, Umeh CA, Montgomery SP, Wirtz VJ. 2016. Estimating the burden of Chagas disease in the United States. *PLoS Negl Trop Dis* 10: e0005033. <https://doi.org/10.1371/journal.pntd.0005033>.
- Bern C, Montgomery SP. 2009. An estimate of the burden of Chagas disease in the United States. *Clin Infect Dis* 49:e52–e54. <https://doi.org/10.1086/605091>.
- Montgomery SP, Parise ME, Dotson EM, Bialek SR. 2016. What do we know about Chagas disease in the United States? *Am J Trop Med Hyg* 95: 1225–1227. <https://doi.org/10.4269/ajtmh.16-0213>.
- Montgomery SP, Starr MC, Cantele PT, Edwards MS, Meymandi SK. 2014. Neglected parasitic infections in the United States: Chagas disease. *Am J Trop Med Hyg* 90:814–818. <https://doi.org/10.4269/ajtmh.13-0726>.
- Lynn MK, Bossak BH, Sandifer PA, Watson A, Nolan MS. 2020. Contemporary autochthonous human Chagas disease in the USA. *Acta Trop* 205: 105361. <https://doi.org/10.1016/j.actatropica.2020.105361>.
- Echeverria LE, Morillo CA. 2019. American Trypanosomiasis (Chagas disease). *Infect Dis Clin North Am* 33:119–134. <https://doi.org/10.1016/j.idc.2018.10.015>.
- Duarte LF, Florez O, Rincon G, Gonzalez CI. 2014. Comparison of seven diagnostic tests to detect *Trypanosoma cruzi* infection in patients in chronic phase of Chagas disease. *Colomb Med (Cali)* 45:61–66. <https://doi.org/10.25100/cm.v45i2.1381>.
- Moore Z, Angheben A, Molina I, Gobbi F, Espasa M, Anselmi M, Salvador F, Tais S, Sánchez-Montalvá A, Pumarola T, Albajar-Viñas P, Sulleiro E. 2016. Serodiscordance in chronic Chagas disease diagnosis: a real problem in non-endemic countries. *Clin Microbiol Infect* 22:788–792. <https://doi.org/10.1016/j.cmi.2016.06.001>.
- WHO. 2002. Control of Chagas disease. Geneva: WHO.
- Gorlin J, Rossmann S, Robertson G, Stallone F, Hirschler N, Nguyen K-A, Gilcher R, Fernandes H, Alvey S, Ajongwen P, Contestable P, Warren H. 2008. Evaluation of a new *Trypanosoma cruzi* antibody assay for blood donor screening. *Transfusion* 48:531–540. <https://doi.org/10.1111/j.1537-2995.2007.01566.x>.
- Tobler LH, Contestable P, Pitina L, Pitina L, Groth H, Shaffer S, Blackburn GR, Warren H, Lee SR, Busch MP. 2007. Evaluation of a new enzyme-linked immunosorbent assay for detection of Chagas antibody in US blood donors. *Transfusion* 47:90–96. <https://doi.org/10.1111/j.1537-2995.2007.01068.x>.
- Cheng KY, Chang C-D, Salbilla VA, Kirchhoff LV, Leiby DA, Schochetman G, Shah DO. 2007. Immunoblot assay using recombinant antigens as a supplemental test to confirm the presence of antibodies to *Trypanosoma cruzi*. *Clin Vaccine Immunol* 14:355–361. <https://doi.org/10.1128/CVI.00401-06>.
- Shah V, Ferrufino L, Gilman RH, Ramirez M, Saenza E, Malaga E, Sanchez G, Okamoto EE, Sherbuck JE, Clark EH, Galdos-Cardenas G, Bozo R, Flores-Franco JL, Colanzi R, Verastegui M, Bern C. 2014. Field evaluation of the InBios Chagas detect plus rapid test in serum and whole-blood specimens in Bolivia. *Clin Vaccine Immunol* 21:1645–1649. <https://doi.org/10.1128/CVI.00609-14>.
- Casandra DR, Steurer FJ, Zcaicki N, Todd CW, editors. 2011. Determination of the sensitivity and specificity of three serodiagnostic assays for Chagas disease by latent class analysis. ASMTM Meeting, Atlanta.
- Wilson EB. 1927. Probable inference, the law of succession, and statistical inference. *J the American Statistical Association* 22:209–212. <https://doi.org/10.1080/01621459.1927.10502953>.
- Yates F. 1934. Contingency tables involving small numbers and the chi square test. *J R Stat Soc* 1:217–235. <https://doi.org/10.2307/2983604>.
- R Core Team. 2018. R: A language and environment for statistical computing 3.5.1. <https://www.R-project.org/>.
- Caballero ZC, Sousa OE, Marques WP, Saez-Alquezar A, Umezawa ES. 2007. Evaluation of serological tests to identify *Trypanosoma cruzi* infection in humans and determine cross-reactivity with *Trypanosoma rangeli* and *Leishmania* spp. *Clin Vaccine Immunol* 14:1045–1049. <https://doi.org/10.1128/CVI.00127-07>.
- Sosa-Estani S, Gamboa-León MR, Del Cid-Lemus J, Althabe F, Alger J, Almendares O, Cafferata ML, Chippaux J-P, Dumonteil E, Gibbons L, Padilla-Raygoza N, Schneider D, Belizán JM, Buekens P, Working Group. 2008. Use of a rapid test on umbilical cord blood to screen for *Trypanosoma cruzi* infection in pregnant women in Argentina, Bolivia, Honduras, and Mexico. *Am J Trop Med Hyg* 79:755–759. <https://doi.org/10.4269/ajtmh.2008.79.755>.
- Umezawa ES, Luquetti AO, Levitus G, Ponce C, Ponce E, Henriquez D, Revollo S, Espinoza B, Sousa O, Khan B, da Silveira JF. 2004. Serodiagnosis of chronic and acute Chagas' disease with *Trypanosoma cruzi* recombinant proteins: results of a collaborative study in six Latin American countries. *J Clin Microbiol* 42:449–452. <https://doi.org/10.1128/JCM.42.1.449-452.2004>.
- Verani JR, Seitz A, Gilman RH, LaFuente C, Galdos-Cardenas G, Kawai V, de LaFuente E, Ferrufino L, Bowman NM, Pinedo-Cancino V, Levy MZ, Steurer F, Todd CW, Kirchhoff LV, Cabrera L, Verastegui M, Bern C. 2009. Geographic variation in the sensitivity of recombinant antigen-based rapid tests for chronic *Trypanosoma cruzi* infection. *Am J Trop Med Hyg* 80: 410–415. <https://doi.org/10.4269/ajtmh.2009.80.410>.
- Kelly EA, Bulman CA, Gunderson EL, Irish AM, Townsend RL, Sakanari JA, Stramer SL, Bern C, Whitman JD. 2021. Comparative performance of latest-generation and FDA-cleared serology tests for the diagnosis of Chagas disease. *J Clin Microbiol* 59:e00158-21. <https://doi.org/10.1128/JCM.00158-21>.
- Whitman JD, Bulman CA, Gunderson EL, Irish AM, Townsend RL, Stramer SL, Sakanari JA, Bern C. 2019. Chagas disease serological test performance in U.S. blood donor specimens. *J Clin Microbiol* 57:e01217-19. <https://doi.org/10.1128/JCM.01217-19>.